D L Carlson Investment Group Inc Bristol Myers Squibb CO Transaction History

D L Carlson Investment Group Inc

  • $507 Million
  • Q1 2025

A detailed history of D L Carlson Investment Group Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, D L Carlson Investment Group Inc holds 24,763 shares of BMY stock, worth $1.11 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
24,763
Holding current value
$1.11 Million
% of portfolio
0.3%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
BUY
$53.9 - $63.11 $1.33 Million - $1.56 Million
24,763 New
24,763 $1.51 Million
Q1 2024

May 14, 2024
SELL
$47.98 - $54.4 $77,343 - $87,692
-1,612 Reduced 4.63%
33,174 $1.8 Million
Q4 2023

Feb 16, 2024
SELL
$48.48 - $57.85 $1.59 Million - $1.9 Million
-32,773 Reduced 48.51%
34,786 $1.78 Million
Q3 2023

Nov 02, 2023
SELL
$57.89 - $64.73 $135,752 - $151,791
-2,345 Reduced 3.35%
67,559 $3.92 Million
Q2 2023

Aug 09, 2023
SELL
$63.71 - $70.74 $29,434 - $32,681
-462 Reduced 0.66%
69,904 $4.47 Million
Q1 2023

May 17, 2023
SELL
$65.71 - $74.53 $403,853 - $458,061
-6,146 Reduced 8.03%
70,366 $4.88 Million
Q4 2022

Feb 13, 2023
SELL
$68.48 - $81.09 $398,690 - $472,105
-5,822 Reduced 7.07%
76,512 $5.51 Million
Q3 2022

Nov 18, 2022
SELL
$0.13 - $76.84 $1,860 - $1.1 Million
-14,315 Reduced 14.81%
82,334 $5.85 Million
Q2 2022

Aug 10, 2022
BUY
$72.62 - $79.98 $19,607 - $21,594
270 Added 0.28%
96,649 $7.44 Million
Q1 2022

May 12, 2022
SELL
$61.48 - $73.72 $32,461 - $38,924
-528 Reduced 0.54%
96,379 $7.04 Million
Q4 2021

Feb 14, 2022
SELL
$53.63 - $62.52 $775,704 - $904,289
-14,464 Reduced 12.99%
96,907 $6.04 Million
Q3 2021

Nov 05, 2021
BUY
$59.17 - $69.31 $187,391 - $219,504
3,167 Added 2.93%
111,371 $6.59 Million
Q2 2021

Aug 12, 2021
BUY
$61.91 - $67.42 $1.6 Million - $1.74 Million
25,801 Added 31.31%
108,204 $7.23 Million
Q1 2021

May 11, 2021
BUY
$59.34 - $66.74 $555,422 - $624,686
9,360 Added 12.81%
82,403 $5.2 Million
Q4 2020

Feb 09, 2021
SELL
$57.74 - $65.43 $149,373 - $169,267
-2,587 Reduced 3.42%
73,043 $4.53 Million
Q3 2020

Nov 13, 2020
BUY
$57.43 - $63.64 $1.77 Million - $1.96 Million
30,746 Added 68.5%
75,630 $4.56 Million
Q2 2020

Aug 13, 2020
BUY
$54.82 - $64.09 $419,044 - $489,903
7,644 Added 20.53%
44,884 $2.64 Million
Q1 2020

May 07, 2020
SELL
$46.4 - $67.43 $810,793 - $1.18 Million
-17,474 Reduced 31.94%
37,240 $2.08 Million
Q4 2019

Feb 10, 2020
SELL
$49.21 - $64.19 $1,181 - $1,540
-24 Reduced 0.04%
54,714 $3.51 Million
Q3 2019

Nov 05, 2019
BUY
$42.77 - $50.71 $470,983 - $558,418
11,012 Added 25.18%
54,738 $2.78 Million
Q2 2019

Aug 19, 2019
SELL
$44.62 - $49.34 $187,359 - $207,178
-4,199 Reduced 8.76%
43,726 $1.98 Million
Q1 2019

May 02, 2019
BUY
$45.12 - $53.8 $164,101 - $195,670
3,637 Added 8.21%
47,925 $2.29 Million
Q4 2018

Feb 12, 2019
SELL
$48.76 - $63.23 $1.4 Million - $1.81 Million
-28,664 Reduced 39.29%
44,288 $2.3 Million
Q3 2018

Nov 13, 2018
BUY
$55.19 - $62.25 $861,626 - $971,847
15,612 Added 27.23%
72,952 $4.53 Million
Q2 2018

Aug 10, 2018
SELL
$50.53 - $62.98 $1.51 Million - $1.88 Million
-29,892 Reduced 34.27%
57,340 $3.17 Million
Q1 2018

May 11, 2018
BUY
$59.92 - $68.98 $1.69 Million - $1.94 Million
28,193 Added 47.75%
87,232 $5.52 Million
Q4 2017

Feb 09, 2018
BUY
$59.94 - $65.35 $304,914 - $332,435
5,087 Added 9.43%
59,039 $3.62 Million
Q3 2017

Nov 13, 2017
BUY
$55.23 - $63.74 $2.98 Million - $3.44 Million
53,952
53,952 $3.44 Million

Others Institutions Holding BMY

# of Institutions
2,706
Shares Held
1.58B
Call Options Held
25.9M
Put Options Held
24.2M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $95.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track D L Carlson Investment Group Inc Portfolio

Follow D L Carlson Investment Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D L Carlson Investment Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on D L Carlson Investment Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email